Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.

Figs stock has lost momentum and remained in a consolidation phase in almost two years. It remained inside the support and ...

Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.

Photo by Kaboompics.com As of 8:53 am on Tuesday, shares of the company declined anew by 50.85 percent to $1.08 each. The ...

In theory, the Academy of Motion Picture Arts and Sciences Annual Awards, better known as the Oscars, recognize the greatest ...

Intermap Technologies surging with demand and profits from geospatial tech for multiple sectors, making it a micro-cap stock ...

Christina, a toxic relationship recovery coach explained the red flags that could mean you're dating a narcissist ...

Iran confirmed the arrest of Italian journalist Cecilia Sala for 'violating the laws of the Islamic Republic,' Iran's ...

Cocrystal Pharma (COCP) stock plunged 40% Tuesday after the company said it plans to extend a Phase 2a challenge study for ...

Having commercialised its prostate cancer imaging tool with resulting strong revenue, Telix Pharmaceuticals (ASX:TLX) could ...

Gilead Sciences bought nearly 950,000 more shares of antiviral-therapeutics developer Assembly as part of an amended ...

Analysts remain cautiously optimistic about the stock’s prospects despite noting its underperformance compared to the broader tech sector. ENPH stock has a consensus rating of “Moderate Buy ...